Skip to main content

Media Category: Innovation

Sphingosine system – pathology and pathway

Written by ParadigMS Foundation on .

This lecture introduces the sphingosine-1-phosphate (S1P) system as a complex, tightly regulated lipid-signaling pathway with relevance beyond Multiple Sclerosis, extending into vascular biology and other neurological diseases. The speaker explains how S1P is produced and transported, how it acts both intracellularly and via surface receptors, and why its biological effects depend on compartment, binding proteins, and the balance between pro-apoptotic ceramide and pro-survival S1P. The talk also links S1P dysregulation to disease mechanisms and emerging research questions,...

Continue reading

Endocannabinoid system – pathology and pathway

Written by ParadigMS Foundation on .

The endocannabinoid system represents a complex and independent neurotransmitter system with a central role in maintaining homeostasis within the nervous and immune systems. In this lecture, Nikolaos Grigoriadis reviewed the biological foundations of the endocannabinoid system, its mechanisms of action in the central nervous system and immune response, and the growing experimental and clinical evidence supporting its neuroprotective and immunomodulatory functions, with particular relevance for Multiple Sclerosis and other neuroinflammatory conditions. Key Insights from the...

Continue reading

Immune reconstitution–pathology and pathway

Written by ParadigMS Foundation on .

In this keynote from Athens presented by Bart Van Wijmeersch, the concept of immune reconstitution therapy (IRT) in multiple sclerosis is examined from a mechanistic and clinical perspective. The presentation focuses on how targeted depletion and controlled repopulation of immune cells may rebalance dysregulated immunity, enhance tolerance, and reshape long-term disease activity. Key Insights from the Lecture: Immune reconstitution as a goal: restoring immune balance and tolerance is presented as a core objective in MS, by resetting dysregulated regulatory and effector cells. The...

Continue reading

B-Cell Clinical aspects: available and future treatment

Written by ParadigMS Foundation on .

In this keynote delivered in Athens, Professor Carlo Pozzilli takes the audience through the past, present and future of anti-CD20 therapies in multiple sclerosis. Starting from the early interferon era and the first monoclonal antibodies, Professor Pozzilli retraces how B-cell depletion moved from a provocative concept to a central pillar of MS management. Drawing on pivotal trials, 10-year extension data and real-world evidence, the discussion adresses why starting high-efficacy therapy early matters, how anti-CD20 agents compare with other high-efficacy options such as natalizumab,...

Continue reading

Patient-reported Outcomes: Novel Examination Techniques to Uncover Disability Accumulation

Written by ParadigMS Foundation on .

Identification of progression needs new (digital) tools: •Which can monitor different symptoma domains •Which can assessment neurological function in a quantitative way •Which are sensitive enough to detect even subtle changes Patient-reported outcomes can assist using innovative instruments to detect progression from the patient perspective. Data should be collected and analyzed on one platform.

Continue reading

New technologies in the neurological field: What can I use today? And what is coming?

Written by ParadigMS Foundation on .

BIOGRAPHY LETIZIA LEOCANI Letizia Leocani is Associate professor of Neurology at Vita-Salute San Raffaele University, Neurologist in the Neurorehabilitation Unit of the Neurological Dep.t and supervisor of the Experimental neurophysiology Unit and of Magnetic IntraCerebral Stimulation (MagICSI) center – Institute of Experimental Neurology, IRCCS Ospedale San Raffaele (COI). After her medical degree, she obtained a PhD in Human Physiology and Neurology specialty and she has been Research Fellow at the Human Motor Control Section of the National Institutes of Health in...

Continue reading

FAQs

Is ParadigMS for free?

Yes, a ParadigMS subscription is free for healthcare practitioniers. 

Do subscriptions auto-renew?
Your subscription will automatically renew on yearly basis. If you cancel your plan, it will not renew at the end of your subscription cycle. 
I am a representative from industry, can I subscribe?

Free subscriptions to ParadigMS are reserved for healthcare practitioners. If you are a representative of the industry please contact us on learning@paradigms.foundation and we would advise you how to get the access to the material. 

What happens if I subscribe as a HCP if I am not?
If you subscribe as a healthcare practitioner and it is proven that you are not a healthcare practitioner, we will cancel your subscription immediately. 
I am a patient, can I subscribe?

ParadigMS is designed specifically for healthcare practitioners, with content and language tailored to their professional needs. While patients cannot subscribe directly, we encourage you to consult your healthcare provider for relevant insights and updates that may benefit you.

Why should I subscribe to ParadigMS's e-platform?

Subscribing to ParadigMS’s e-platform gives you access to up-to-date information and valuable learning materials on multiple sclerosis and NMO, along with expert insights and the latest innovations in the field. It’s an essential resource for staying informed and enhancing your knowledge in MS care.

How can I cancel my subscription?
You can cancel your subscription in your account settings. 
Can I financially support ParadigMS?

Yes, you can financially support ParadigMS! We welcome donations to help us continue our mission of advancing multiple sclerosis education and research. Your contribution directly supports the creation of educational resources, expert discussions, and innovative projects in MS care. Visit our donation page to learn more about how you can make a difference: ParadigMS Donate.